Journal of the Endocrine Society · 2025
Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phillip Moshe, Abuzzahab M Jennifer, Pietropoli Alberto, Ferran Jean-Marc, Højby Michael, Kelepouris Nicky, Kotnik Primož, Polak Michel, Sävendahl Lars
Аннотация
CONTEXT: GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited.
OBJECTIVE: To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH).
METHODS: This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged <18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-naïve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for ≤10 years.
RESULTS: The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was -1.21 (1.09) and -0.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals.
CONCLUSION: GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile.
OBJECTIVE: To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH).
METHODS: This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged <18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-naïve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for ≤10 years.
RESULTS: The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was -1.21 (1.09) and -0.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals.
CONCLUSION: GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile.